<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.102039</article-id><article-id pub-id-type="publisher-id">TCM-41357</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210200000_67309169.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性
  Effect of Yinghuang Qingfei Capsule and Lopinavir/Ritonavir Treatment in Patients with Mild COVID-19
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>阎</surname><given-names>昱升</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>屈</surname><given-names>金艳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>艳蓉</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>范</surname><given-names>伏元</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汤</surname><given-names>渝玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>尚</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>湖南中医药大学第一附属医院，湖南 长沙</addr-line></aff><aff id="aff2"><addr-line>长沙市第一医院呼吸内科，湖南 长沙</addr-line></aff><aff id="aff3"><addr-line>湖南安邦制药股份有限公司，湖南 长沙</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>02</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>284</fpage><lpage>290</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性。方法：选取隔离病房收治的普通型COVID-19病毒感染患者40例，按随机数字法，随机分配为对照组20例和治疗组20例，对照组予以洛匹那韦/利托那韦治疗，治疗组在对照组基础上加用银黄清肺胶囊治疗。比较2组临床治愈率、临床症状改善时间、超敏C反应蛋白(hs-CRP)和降钙素原(PCT)含量，以及不良反应发生率。结果：治疗14天后，治疗组退热时间、咳嗽消失时间明显短于对照组(P &lt; 0.05)，且hs-CRP含量明显降低，PCT异常患者全部转变为正常，差异有统计学意义(P &lt; 0.05)。两组总有效率、不良反应发生率比较，差异无统计学意义(P &gt; 0.05)。结论：银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效确切，可以缩短患者症状消退时间，改善炎症指标，且安全性较高。 Objective: To evaluate the clinical efficacy and safety of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection. Methods: Forty patients with mild COVID-19 virus infection admitted to the isolation ward were randomly divided into two groups according to the random number method, 20 patients in the control group and 20 patients in the experimental group. The control group was treated with lopinavir/ritonavir. The experimental group was treated with Yinghuang Qingfei capsule on the basis of the control group. The clinical cure rate, the improvement time of clinical symptoms, the content of high sensitive C-reactive protein (hs-CRP) and procalcitonin (PCT) and the incidence of adverse reactions were compared between the two groups. Results: After 14 days of treatment, the time of fever reduction and cough disappearance in the experimental group was significantly shorter than that in the control group (P &lt; 0.05). And the content of hs-CRP was significantly reduced, and all patients with abnormal PCT turned to normal, the difference was statistically significant (P &lt; 0.05). There was no significant difference in the total effective rate and the incidence of adverse reactions between the two groups (P &gt; 0.05). Conclusion: The clinical efficacy of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection is definite, which can shorten the time of symptom resolution in patients and improve inflammation indicators with high safety. 
  
 
</p></abstract><kwd-group><kwd>银黄清肺胶囊，洛匹那韦/利托那韦，COVID-19，超敏C反应蛋白，降钙素原, Yinghuang Qingfei Capsule</kwd><kwd> Lopinavir/Ritonavir</kwd><kwd> COVID-19</kwd><kwd> Hs-CRP</kwd><kwd> PCT</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性。方法：选取隔离病房收治的普通型COVID-19病毒感染患者40例，按随机数字法，随机分配为对照组20例和治疗组20例，对照组予以洛匹那韦/利托那韦治疗，治疗组在对照组基础上加用银黄清肺胶囊治疗。比较2组临床治愈率、临床症状改善时间、超敏C反应蛋白(hs-CRP)和降钙素原(PCT)含量，以及不良反应发生率。结果：治疗14天后，治疗组退热时间、咳嗽消失时间明显短于对照组(P &lt; 0.05)，且hs-CRP含量明显降低，PCT异常患者全部转变为正常，差异有统计学意义(P &lt; 0.05)。两组总有效率、不良反应发生率比较，差异无统计学意义(P &gt; 0.05)。结论：银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效确切，可以缩短患者症状消退时间，改善炎症指标，且安全性较高。</p></sec><sec id="s2"><title>关键词</title><p>银黄清肺胶囊，洛匹那韦/利托那韦，COVID-19，超敏C反应蛋白，降钙素原</p></sec><sec id="s3"><title>Effect of Yinghuang Qingfei Capsule and Lopinavir/Ritonavir Treatment in Patients with Mild COVID-19</title><p>Yusheng Yan<sup>1</sup>, Jinyan Qu<sup>2</sup>, Yanrong Wei<sup>3</sup>, Fuyuan Fan<sup>3</sup>, Yuling Tang<sup>1</sup>, Shang Gao<sup>2*</sup></p><p><sup>1</sup>The Respiratory Department in the First Hospital of Changsha, Changsha Hunan</p><p><sup>2</sup>Hunan Anbang Pharmaceutical Co., Ltd., Changsha Hunan</p><p><sup>3</sup>The First Hospital of Hunan University of Chinese Medicine, Changsha Hunan</p><p><img src="//html.hanspub.org/file/21-2270660x5_hanspub.png" /></p><p>Received: Feb. 19<sup>th</sup>, 2021; accepted: Mar. 23<sup>rd</sup>, 2021; published: Mar. 30<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/21-2270660x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the clinical efficacy and safety of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection. Methods: Forty patients with mild COVID-19 virus infection admitted to the isolation ward were randomly divided into two groups according to the random number method, 20 patients in the control group and 20 patients in the experimental group. The control group was treated with lopinavir/ritonavir. The experimental group was treated with Yinghuang Qingfei capsule on the basis of the control group. The clinical cure rate, the improvement time of clinical symptoms, the content of high sensitive C-reactive protein (hs-CRP) and procalcitonin (PCT) and the incidence of adverse reactions were compared between the two groups. Results: After 14 days of treatment, the time of fever reduction and cough disappearance in the experimental group was significantly shorter than that in the control group (P &lt; 0.05). And the content of hs-CRP was significantly reduced, and all patients with abnormal PCT turned to normal, the difference was statistically significant (P &lt; 0.05). There was no significant difference in the total effective rate and the incidence of adverse reactions between the two groups (P &gt; 0.05). Conclusion: The clinical efficacy of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection is definite, which can shorten the time of symptom resolution in patients and improve inflammation indicators with high safety.</p><p>Keywords:Yinghuang Qingfei Capsule, Lopinavir/Ritonavir, COVID-19, Hs-CRP, PCT</p><disp-formula id="hanspub.41357-formula27"><graphic xlink:href="//html.hanspub.org/file/21-2270660x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-2270660x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-2270660x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2019年底在湖北武汉地区发现的新的病毒性肺炎受到了全球的重点关注。在2020年2月11日，世界卫生组织将其正式命名为“COVID-19”(Corona Virus Disease-9)，并将COVID-19的病原体命名为SARS-CoV-2 (此前称2019-nCoV) [<xref ref-type="bibr" rid="hanspub.41357-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref3">3</xref>]。已有研究发现该病原体是一种有包膜的、非节段的正单链 RNA病毒，主要通过病毒表面的S蛋白识别靶细胞上的ACE2受体进入细胞造成感染，其结合能力比SARS病毒高出10~20倍，具有高致病性和极强的传染性，人群普遍易感，疾病初期以发热、咳嗽为主要症状，70%以上患者表现为轻型和普通型 [<xref ref-type="bibr" rid="hanspub.41357-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref6">6</xref>]。</p><p>目前对于COVID-19诊断试剂、疫苗、抗体的研究已陆续开展，但尚未发现特效治疗药物。而在这次战役中，我国中医药传统医学发挥了重要的作用，中西医结合治疗在改善患者症状、减少患者轻症向重症转化、促进出院患者炎症吸收和肺功能康复等方面有非常好的效果 [<xref ref-type="bibr" rid="hanspub.41357-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref10">10</xref>]。银黄清肺胶囊由葶苈子、炙麻黄、苦杏仁、枇杷叶、浙贝母、银杏叶等14味中药材制备而成，前期研究表明其具有显著的抗病毒、止咳、化痰等功效 [<xref ref-type="bibr" rid="hanspub.41357-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref14">14</xref>]，被列入《湖南省新型冠状病毒感染的肺炎中医药诊疗方案(第三版)》推荐用药。本文通过总结我院收治使用银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒患者的临床研究，为普通型COVID-19的防治提供新的治疗方法和思路。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>纳入研究对象来自我院2020年2月5日~2020年2月20日收治的根据国家卫生健康委员会颁布的《新型冠状病毒感染的肺炎诊疗方案第五版》 [<xref ref-type="bibr" rid="hanspub.41357-ref15">15</xref>] 确诊为COVID-19感染者40例，采用完全随机化方法，将40个患者按照就诊顺序编号，从随机数字表中获得患者随机数，随机数字为奇数的患者列入对照组，随机数字为偶数的患者列入治疗组，对照组和治疗组例数均为20例。两组受试者的年龄、性别、病程比较差异无统计学意义(见表1)。本研究符合药物临床试验质量管理规范，研究方案经长沙市第一医院伦理委员会2020年2月1日审核批准(伦理批件号：KX-2020036)。</p></sec><sec id="s6_2"><title>2.2. 纳入与排除标准</title><p>纳入标准：① 新冠核酸检测阳性，根据国家卫生健康委员会颁布的《新型冠状病毒感染的肺炎诊疗方案第五版》确诊为新型冠状病毒肺炎，临床分型为普通型。② 年龄在18~75岁之间。</p><p>排除标准：① 新型冠状病毒肺炎为轻型、重型、危重型者；② 不愿意接受中成药药物治疗者。③ 无症状感染者。④ 年龄大于75岁或小于18岁。⑤ 排除其他心肺疾病。</p></sec><sec id="s6_3"><title>2.3. 药物治疗方法</title><p>对照组患者接受常规西医治疗，根据《新型冠状病毒感染的肺炎诊疗方案第五版》推荐方案，给予洛匹那韦/利托那韦片(AbbVie Ltd，批准文号：H20130693)抗病毒治疗，2片/次(每片含洛匹那韦200 mg，利托那韦50 mg)，2次/d，以及对症及支持治疗，病情监测。治疗组在对照组基础上加用银黄清肺胶囊(湖南安邦制药股份有限公司，批准文号：Z20020075)，3粒/次(0.15 g/粒)，3次/日。两组用药疗程均为14天。</p></sec><sec id="s6_4"><title>2.4. 观察指标与评价标准</title><p>比较临床症状(咳嗽、发热)消失时间、临床疗效、不良反应。1) 临床疗效评价标准如下：① 体温恢复正常，咳嗽、发热等症状消失为治愈。② 体温恢复正常，咳嗽等症状可见显著好转为有效。③ 体温、咳嗽症状有加重，且转为重症为无效。总有效率计算方法是① + ②，除以总例数。2) 比较两组临床症状(咳嗽、发热)消退时间。3) 比较治疗前后两组hs-CRP含量和PCT转变情况。4) 观察两组不良反应发生情况。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>采用SPSS 20.0统计学软件进行数据处理，计量资料以( x &#175; &#177; S )表示，采用t检验；计数资料以相对数表示，采用x<sup>2</sup>检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>1) 两组临床一般资料比较：入组时，对照组和治疗组的患者性别组成、年龄、病程情况等比较，差异均无统计学意义(P &gt; 0.05)，具有可比性。详见表1。</p><p>2) 两组患者的总有效率、治愈率比较：治疗14天后，治疗组和对照组的总有效率比较，差异无统计学意义(P &gt; 0.05)，但治疗组治愈率高于对照组。详见表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data of patients in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle"  colspan="2"  >性别</th><th align="center" valign="middle" >年龄</th><th align="center" valign="middle" >病程</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >女</td><td align="center" valign="middle" >(岁 x &#175; &#177; S )</td><td align="center" valign="middle" >(天 x &#175; &#177; S )</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >36.18 &#177; 8.36</td><td align="center" valign="middle" >5.52 &#177; 3.15</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >37.27 &#177; 8.92</td><td align="center" valign="middle" >5.58 &#177; 3.11</td></tr></tbody></table></table-wrap><p>表1. 两组患者的一般资料比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the total effective rate and cure rate of patients in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治愈</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >100%</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >100%</td></tr></tbody></table></table-wrap><p>表2. 两组患者的总有效率、治愈率比较</p><p>3) 两组患者的发热消退时间、咳嗽消退时间比较：治疗14天后，治疗组的发热消退时间、咳嗽消失时间均明显短于对照组，差异有统计学意义(P &lt; 0.05)。详见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the time of fever reduction and cough disappearance of patients in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >发热消退时间(天)</th><th align="center" valign="middle" >咳嗽消失时间(天)</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2.5 &#177; 0.2</td><td align="center" valign="middle" >8.5 &#177; 2.1</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >1.6 &#177; 0.1</td><td align="center" valign="middle" >5.8 &#177; 1.2</td></tr></tbody></table></table-wrap><p>表3. 两组患者的发热消退时间、咳嗽消退时间比较</p><p>4) 两组患者的hs-CRP和PCT比较：治疗14天后，与对照组相比，治疗组患者的hs-CRP含量明显降低，PCT异常患者全部转变为正常，差异有统计学意义(P &lt; 0.05)。详见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of the hs-CRP and PCT of patients in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  colspan="2"  >hs-CRP</th><th align="center" valign="middle"  colspan="2"  >PCT</th></tr></thead><tr><td align="center" valign="middle" >疗前</td><td align="center" valign="middle" >疗后</td><td align="center" valign="middle" >疗前</td><td align="center" valign="middle" >疗后</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >17.13 &#177; 14.69</td><td align="center" valign="middle" >8.69 &#177; 8.03</td><td align="center" valign="middle" >4例异常</td><td align="center" valign="middle" >0例异常</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >17.65 &#177; 18.14</td><td align="center" valign="middle" >4.74 &#177; 5.05</td><td align="center" valign="middle" >6例异常</td><td align="center" valign="middle" >4例异常</td></tr></tbody></table></table-wrap><p>表4. 两组患者的hs-CRP和PCT比较</p><p>5) 两组不良反应发生率比较：治疗14天后，两组的不良反应发生率比较，差异无统计学意义(P &gt; 0.05)，详见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of the incidence of adverse reactions in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >恶心</th><th align="center" valign="middle" >肝功能受损</th><th align="center" valign="middle" >轻微腹泻</th><th align="center" valign="middle" >合计</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8</td></tr></tbody></table></table-wrap><p>表5. 两组不良反应发生率比较</p></sec><sec id="s8"><title>4. 讨论</title><p>至新冠疫情以来，我国根据临床经验和临床试验结果持续更新新冠肺炎指南，到目前为止已经更新到第8版。大量研究表明，新型冠状病毒人群普遍易感，多数为轻型和普通型的患者 [<xref ref-type="bibr" rid="hanspub.41357-ref16">16</xref>]，且多数患者有咳嗽、发热等症状，少部分还有腹泻等症状。在最初的新冠肺炎指南主要推荐的是洛匹那韦/利托那韦、利巴韦林等西药抗病毒治疗。本病属于中医疫病范畴，病因为感受疫戾之气，病位在肺，基本病机特点为“湿、热、毒、瘀”。故中医治疗的重点在于“宣肺、清肺、祛湿、解毒”。许多研究表明，此次新冠肺炎轻症患者的中医症候多为湿热蕴肺证型 [<xref ref-type="bibr" rid="hanspub.41357-ref17">17</xref>]。银黄清肺胶囊处方为“麻杏石甘汤”和“葶苈大枣泻肺汤”加减而成，具有宣肺清热、止咳化痰之功。本品首选葶苈子、炙麻黄为君药，以葶苈子之寒性以祛肺热，下气行水以驱痰涎，泻肺平喘以治其主症；麻黄功善发汗利水，宣肺平喘。两药合用，一宣一降，共同针对痰、咳、喘的主症而通达肺经，以行宣肺降气、止咳平喘之效。苦杏仁性专降泄，兼能润肠通便；浙贝母、枇杷叶清肺化痰散结、降气止咳；银杏叶化痰平喘，兼能解除痰热壅肺造成的瘀滞状态，又能收敛肺气，佐制麻黄，防其发散太过耗伤肺气，四药共为臣药。石菖蒲、穿山龙、一枝蒿、大青叶、五味子、枳实、生石膏共为佐药。石菖蒲功善开窍豁痰、理气活血、散风祛湿，穿山龙活血、祛痰、利水。一枝蒿、大青叶清肺经浊热热毒，并改善痰热造成的瘀滞状态。用五味子配麻黄，一宣一敛，宣中有敛，散中有收，使宣降有序，本源兼顾。借枳实、生石膏之力，加强君臣药消痰除满、清热泻火之功。方中用甘草调和诸药而为使药。诸药配合，清肺化痰，止咳平喘，使肺热清，痰浊祛，咳喘平，诸证向愈。</p><p>在新冠肺炎防治方案中，麻杏石甘汤出现频次最多，在国家级及省市级防治方案均位于首位，并在各期不同阶段均有应用，成为肺部感染性疾病的核心方剂 [<xref ref-type="bibr" rid="hanspub.41357-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref19">19</xref>]。研究表明，麻杏石甘汤对COVID-19的病毒复制和细胞因子风暴具有显著的调节作用，能促进TH细胞分化和T细胞稳态抑制病毒复制，负调控白介素、TNF、整合素等免疫炎症因子消除细胞因子风暴 [<xref ref-type="bibr" rid="hanspub.41357-ref20">20</xref>]。麻杏石甘汤和葶苈大枣泻肺汤联用能有效改善老年社区获得性肺炎、小儿肺炎等肺部感染性疾病的症状，降低CRP、ESR、PCT，缩短临床症状消退时间，改善肺功能，促进患者康复等 [<xref ref-type="bibr" rid="hanspub.41357-ref21">21</xref>]。</p><p>病理研究表明，新冠病毒主要引起深部气道和肺泡损伤为特征的炎症反应，支气管腔内可见黏液和黏液栓形成，进而影响肺通气换气功能。由于渗出物的黏稠度较高，所以很难以痰液的形式咳出，针对这种情况，有必要采取有效措施以减少渗出物的产生并促进渗出物的排出，从而减轻气道阻塞，改善肺通气换气功能 [<xref ref-type="bibr" rid="hanspub.41357-ref22">22</xref>]。呼吸道黏液或痰栓属于中医学“痰”的范畴，银黄清肺胶囊在“麻杏石甘汤”和“葶苈大枣泻肺汤”基础上加入浙贝母、枳实、苦杏仁、枇杷叶等，增强了清肺热、祛痰浊、止咳的功效，有效改善COVID-19患者的“痰液阻塞”症状。hs-CRP是一种在感染中显著升高的急性反应蛋白，此次COVID-19疫情中，多数患者的hs-CRP随病情的进行性发展而升高，研究显示，血浆hs-CRP水平与COVID-19的严重程度呈正相关，当hs-CRP与IL-6等炎症细胞因子水平升高，预测与机械通气治疗方案高度相关，对于指导治疗方案升级具有重要意义 [<xref ref-type="bibr" rid="hanspub.41357-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref25">25</xref>]。PCT是细菌感染的监测指标，大多数COVID-19患者入院时血清PCT水平正常或略高，部分患者发生继发感染后，PCT明显升高 [<xref ref-type="bibr" rid="hanspub.41357-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref27">27</xref>]。hs-CRP和PCT是COVID-19重要的炎症指标，对于疾病发展转归具有重要的意义。已有研究显示，银黄清肺胶囊具有显著的抗病毒、抗炎、抑菌、止咳、化痰作用，其主要分子靶标最大的功能模块由参与炎症–免疫相关通路的药物靶标组成 [<xref ref-type="bibr" rid="hanspub.41357-ref28">28</xref>]，能显著降低急性支气管炎、下呼吸道肺炎支原体感染、支气管扩张急性加重期、慢性阻塞性肺疾病急性加重期等呼吸道感染性疾病患者的CRP、PCT水平 [<xref ref-type="bibr" rid="hanspub.41357-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.41357-ref32">32</xref>]。</p><p>本研究中西医联合治疗的结果显示，治疗组总有效率与对照组相当，且治疗组咳嗽、发热等临床症状消退时间短于对照组，且hs-CRP含量明显降低，PCT异常患者全部转变为正常，不良反应发生率组间无差异，表明银黄清肺胶囊联合洛匹那韦/利托那韦片治疗普通型新冠患者的临床疗效确切，可以缩短患者临床症状消退时间，改善炎症指标，且安全性较高，可以加快机体康复，实现多途径、多靶点治疗。由于当时的情况限制，本研究的样本量较小，观察指标尚有待进一步完善。若情况允许，将进一步开展更为深入的研究以探讨银黄清肺胶囊治疗新冠肺炎的临床疗效和作用机制。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，银黄清肺胶囊联合洛匹那韦/利托那韦片治疗普通型新冠的临床疗效确切，可以缩短患者症状消退时间，改善炎症指标，且安全性较高，值得临床推广应用。</p></sec><sec id="s10"><title>基金项目</title><p>湖南省科技厅：湖南省经典名方工程技术研究中心(2018TP2034)。</p></sec><sec id="s11"><title>文章引用</title><p>阎昱升,屈金艳,魏艳蓉,范伏元,汤渝玲,高 尚. 银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性Effect of Yinghuang Qingfei Capsule and Lopinavir/Ritonavir Treatment in Patients with Mild COVID-19[J]. 中医学, 2021, 10(02): 284-290. https://doi.org/10.12677/TCM.2021.102039</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41357-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">赵文明, 宋述慧, 陈梅丽, 邹东, 马利娜, 马英克, 李茹姣, 郝丽丽, 李翠萍, 田东梅, 唐碧霞, 王彦青, 朱军伟, 陈焕新, 章张, 薛勇彪, 鲍一明. 2019新型冠状病毒信息库[J]. 遗传, 2020, 42(2): 212-221.</mixed-citation></ref><ref id="hanspub.41357-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王露莹, 陈品儒, 郑国湾, 漆楠, 杨科. 新型冠状病毒检测方法的研究进展[J]. 现代药物与临床, 2020, 35(3): 411-416.</mixed-citation></ref><ref id="hanspub.41357-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张诗琬, 喻雪琴, 陈芳, 敬雪明, 梅怡晗, 梅小平. 新型冠状病毒肺炎的研究进展[J]. 山东医药, 2020, 60(13): 110-114.</mixed-citation></ref><ref id="hanspub.41357-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Guan, W.-J., Ni, Z.-Y., Hu, Y., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. &lt;br&gt;https://doi.org/10.1056/NEJMoa2002032</mixed-citation></ref><ref id="hanspub.41357-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Smriti, M. (2020) Why Does the Coronavirus Spread So Easily between People? Nature, 579, 183.  
&lt;br&gt;https://doi.org/10.1038/d41586-020-00660-x</mixed-citation></ref><ref id="hanspub.41357-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中国病毒病杂志, 2020, 10(2): 81-87.</mixed-citation></ref><ref id="hanspub.41357-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">高树明, 马英, 杨丰文, 张俊华, 于春泉. 张伯礼: 中医药在防治新型冠状病毒肺炎全过程发挥作用[J]. 天津中医药, 2020, 37(2): 121-124.</mixed-citation></ref><ref id="hanspub.41357-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">白爽, 李澎, 赵立. 抗病毒与中医药治疗方案变迁——对新型冠状病毒肺炎患者转归趋势的宏观影响[J]. 中国临床药理学杂志, 2020, 36(7): 912-917.</mixed-citation></ref><ref id="hanspub.41357-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">史锁芳, 刘清泉. 从“江夏方舱中医模式”探讨中医药在新型冠状病毒肺炎治疗中的价值[J]. 江苏中医药, 2020, 52(4): 11-14.</mixed-citation></ref><ref id="hanspub.41357-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hu, K., Guan, W.-J., Bi, Y., et al. (2020) Efficacy and Safety of Lianhuaqingwen Capsules, a Repurposed Chinese Herb, in Patients with Coronavirus Disease 2019: A Multicenter, Prospective, Randomized Controlled Trial. Phytomedicine, 2020, Article ID: 153242. &lt;br&gt;https://doi.org/10.1016/j.phymed.2020.153242</mixed-citation></ref><ref id="hanspub.41357-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">彭志, 卢芳国, 屈金艳, 李玲, 范伏元, 那婧婧, 李湘兰. 银黄清肺胶囊含药血清体外抗呼吸道合胞病毒实验研究[J]. 湖南中医药大学学报, 2016, 36(2): 40-43.</mixed-citation></ref><ref id="hanspub.41357-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李湘兰, 卢芳国, 易登峰, 李玲, 范伏元, 葛资宇, 彭志. 银黄清肺胶囊含药血清体外抗流感病毒实验研究[J]. 中华中医药学刊, 2015, 33(5): 1107-1109.</mixed-citation></ref><ref id="hanspub.41357-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">邱瑜, 张思, 张妙红. 银黄清肺胶囊对幼龄大鼠流感病毒肺炎的保护作用及机制研究[J]. 中南药学, 2018, 16(9): 1240-1243.</mixed-citation></ref><ref id="hanspub.41357-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李妲, 范伏元. 银黄清肺胶囊合头孢西丁治疗社区获得性肺炎的临床观察[J]. 中医药导报, 2015, 21(16): 71-72+75.</mixed-citation></ref><ref id="hanspub.41357-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">新型冠状病毒感染的肺炎诊疗方案(试行第五版) [J]. 江苏中医药, 2020, 52(2): 96+95.</mixed-citation></ref><ref id="hanspub.41357-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李力, 李琦, 程金波, 毛梅, 艾山木, 谭虎, 杨仕明, 胡明冬, 任小宝, 王斌, 张宏雁, 徐迪雄, 毛青, 曹国强. 新型冠状病毒肺炎患者分层治疗与中医辅助治疗方案[J]. 第三军医大学学报, 2020, 42(4): 427-430.</mixed-citation></ref><ref id="hanspub.41357-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李修洋, 宋斌, 雷烨, 李青伟, 郑玉娇, 刘文科, 王强, 朱向东, 黄飞剑, 沈仕伟, 周毅德, 杨映映, 张培, 林家冉, 赵林华. 《新型冠状病毒肺炎诊疗方案(试行第六版)》中医诊疗方案解读[J]. 吉林中医药, 2020, 40(6): 701-708.</mixed-citation></ref><ref id="hanspub.41357-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">唐璇, 佟琳, 郭非非, 唐仕欢, 杨洪军. 基于TCMATCOV平台的常用经典名方治疗新型冠状病毒肺炎潜在作用分析[J]. 中国中药杂志, 2020, 45(13): 3028-3034.</mixed-citation></ref><ref id="hanspub.41357-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">张云, 杨卉, 何轩辉, 吴广均, 李军. 麻杏石甘汤治疗新冠肺炎细胞因子风暴的网络药理学分析[J]. 世界中医药, 2020, 15(13): 1908-1913.</mixed-citation></ref><ref id="hanspub.41357-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">陈恩超. 麻杏石甘汤合葶苈大枣泻肺汤加减治疗小儿肺炎的效果[J]. 中国医学创新, 2019, 16(11): 141-144.</mixed-citation></ref><ref id="hanspub.41357-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">谭亚云, 梁冬. 麻杏石甘汤合葶苈大枣泻肺汤加减辅助治疗社区中老年患者获得性肺炎的疗效分析[J]. 中国实验方剂学杂志, 2016, 22(5): 202-205.</mixed-citation></ref><ref id="hanspub.41357-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">孙惠敏, 徐锋, 张玲, 魏聪, 陈杰勇, 王秋欣, 贾振华. 连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察[J]. 中国实验方剂学杂志, 2020, 26(14): 29-34.</mixed-citation></ref><ref id="hanspub.41357-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.-P., Li, G.-M., He, J., et al. (2020) Combined Use of the Neutrophil-to-Lymphocyte Ratio and CRP to Predict 7-Day Disease Severity in 84 Hospitalized Patients with COVID-19 Pneumonia: A Retrospective Cohort Study. Annals of Translational Medicine, 8, 635. &lt;br&gt;https://doi.org/10.21037/atm-20-2372</mixed-citation></ref><ref id="hanspub.41357-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tobias, H., Vindi, J., Chiara, A., et al. (2020) Elevated Levels of IL-6 and CRP Predict the Need for Mechanical Ventilation in COVID-19. The Journal of Allergy and Clinical Immunology, 146, 128-136.  
&lt;br&gt;https://doi.org/10.1016/j.jaci.2020.05.008</mixed-citation></ref><ref id="hanspub.41357-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Zheng, K.I., Liu, S.D., et al. (2020) Plasma CRP Level Is Positively Associated with the Severity of COVID-19. Annals of Clinical Microbiology and Antimicrobials, 19, 18. &lt;br&gt;https://doi.org/10.1186/s12941-020-00362-2</mixed-citation></ref><ref id="hanspub.41357-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">白露, 刘泽世, 周柯, 徐修礼. 新型冠状病毒肺炎临床实验室相关检测现状[J/OL]. 检验医学与临床, 2020.  
http://kns.cnki.net/kcms/detail/50.1167.R.20200323.1709.002.html</mixed-citation></ref><ref id="hanspub.41357-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">昌仲勇, 杨为斌, 王强, 廖国林. 血清hs-CRP、IL-6、PCT对新型冠状病毒肺炎患者的诊断及预后评估的临床意义[J]. 现代药物与临床, 2020, 35(3): 417-420.</mixed-citation></ref><ref id="hanspub.41357-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Yu, G.H., Zhang, Y.Q., Ren, W.Q., et al. (2016) Network Pharmacology-Based Identification of Key Pharmacological Pathways of Yin-Huang-Qing-Fei Capsule Acting on Chronic Bronchitis. International Journal of Chronic Obstructive Pulmonary Disease, 11, 85-94. &lt;br&gt;https://doi.org/10.2147/COPD.S121079</mixed-citation></ref><ref id="hanspub.41357-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">范伏元, 李妲. 银黄清肺胶囊治疗急性气管-支气管炎风热犯肺证60例疗效观察[J]. 中医药导报, 2014, 20(1): 36-37.</mixed-citation></ref><ref id="hanspub.41357-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">何薇, 李明晖, 苏美霞, 马建永. 银黄清肺胶囊联合左氧氟沙星治疗下呼吸道肺炎支原体感染的临床研究[J]. 中华中医药学刊, 2016, 34(6): 1418-1420.</mixed-citation></ref><ref id="hanspub.41357-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">蒋牧, 徐旭东, 顾靖华. 银黄清肺胶囊辅助治疗支气管扩张急性加重期临床研究[J]. 新中医, 2019(8): 113-116.</mixed-citation></ref><ref id="hanspub.41357-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">蔡剑英, 陶学芳. 银黄清肺胶囊治疗COPD急性加重期患者的疗效观察及对血清PCT、CRP水平的影响[J]. 中国中医药科技, 2020, 27(2): 279-280.</mixed-citation></ref></ref-list></back></article>